NCT03732274View on ClinicalTrials.gov

Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 11, 2019

Primary Completion Date

May 17, 2024

Study Completion Date

May 17, 2024

Conditions
Non-Small Cell Lung Cancer Metastatic
Interventions
DRUG

TEW-7197

TEW-7197 will be administered orally for 5 days per week (5D/W) at the same time in the morning and evening (BID) approximately 12 hours apart. Durvalumab will be administered as a dose of 1500 mg every 4weeks.

Trial Locations (4)

Unknown

ChungBuk national university hospital, Chungju

National Cancer Center, Goyang-si

Yeonsei University Hospital, Seoul

The Catholic univ of korea st.vincent's hospital, Suwon

Sponsors

Lead Sponsor

MedPacto, Inc.

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

MedPacto, Inc.

INDUSTRY